These grants aim to encourage collaboration between technology developers and clinical cancer immunologists and to generate the proof-of-principle of a novel platform technology in bioinformatics, ex vivo or in silico modeling systems, immunological or tumor profiling instrumentation, methods, reagents and assays, or other relevant technologies that can enable clinician scientists to generate deeper insights into the mechanisms of action of effective or ineffective cancer immunotherapies.
Funding & Duration
The Cancer Research Institute Technology Impact Award provides seed funding of up to USD $200,000 (approx. AUD $281,000) to be used over 12-24 months to address the gap between technology development and clinical application of cancer immunotherapies.
- Applicants must hold a faculty appointment as a tenure-track assistant professor (or higher rank) at the time of award activation.
- The grant will be awarded to a scientist who describes an extraordinarily novel, yet practical research plan that is creative and technically sophisticated.
- Joint submissions from collaborators will also be considered. (The collaborators will share the award.) Each collaborator must meet the eligibility criteria.
- Selected projects that meet their 12 and 24 month milestones may be eligible for follow-on funding that will enable the established proof-of-concept technology to be developed into a methodology that improves cancer immunotherapy research worldwide.
Submission Requirements & Due Dates
- 15 November 2018 – Letter of Intent (LOI) submitted to Sponsor
- 8 April 2019 – invited applications submitted for internal review.
- Please email firstname.lastname@example.org if you are considering applying for this scheme.
- See also: Submitting an Application to Research Services for Review